Home > Boards > US Listed > Biotechs > Chembio Diagnostics (CEMI)

CEMI's COVID-19 diagnostic tests results in 15 minutes

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
~ Blue ~ Member Profile
Followed By 2,539
Posts 114,540
Boards Moderated 6
Alias Born 08/25/10
160x600 placeholder
Chembio Announces EUA Submission for DPP Respiratory Antigen Panel GlobeNewswire Inc. - 9/22/2021 8:00:00 AM
NeuroMetrix, Reneo Pharmaceuticals leads healthcare gainers; Cassava Sciences, Applied Therapeutics among major losers Seeking Alpha - 8/27/2021 11:06:22 AM
Chembio Launches Commercial Distribution of Third-Party COVID-19 Antigen Assay GlobeNewswire Inc. - 8/27/2021 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/9/2021 4:58:31 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/5/2021 4:32:44 PM
Chembio Diagnostics Reports Second Quarter 2021 Financial Results GlobeNewswire Inc. - 8/5/2021 4:05:00 PM
Chembio Diagnostics to Report Second Quarter 2021 Financial Results on August 5, 2021 GlobeNewswire Inc. - 7/22/2021 5:03:53 PM
Chembio Diagnostics gets $4M HIV test purchase order Seeking Alpha - 7/22/2021 1:03:18 PM
Chembio Diagnostics Receives $4 Million HIV Test Purchase Order Supported by The Global Fund GlobeNewswire Inc. - 7/22/2021 12:49:39 PM
NeuroMetrix stock joins Reddit-driven rally with 60% rise in Q2 revenue Seeking Alpha - 7/22/2021 10:00:48 AM
Chembio Diagnostics Bags $28.3M Oder for SARS-CoV-2 Antigen Tests from Brazil TipRanks - 7/22/2021 2:53:30 AM
Chembio surges on purchase order for COVID—19 antigen test from Brazil Seeking Alpha - 7/21/2021 8:12:26 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/21/2021 6:04:51 AM
Chembio Diagnostics Receives $28.3 Million Purchase Order from Bio-Manguinhos for DPP SARS-CoV-2 Antigen Tests in Brazil GlobeNewswire Inc. - 7/20/2021 10:56:14 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/19/2021 5:29:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/19/2021 5:14:54 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/12/2021 8:30:23 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/25/2021 5:21:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/10/2021 4:06:31 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 5/13/2021 9:27:27 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 5/13/2021 9:26:04 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 5/7/2021 6:10:06 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/6/2021 5:29:08 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/6/2021 4:30:47 PM
Chembio Diagnostics EPS beats by $0.10, beats on revenue Seeking Alpha - 5/6/2021 4:28:28 PM
~ Blue ~   Thursday, 07/22/21 10:36:02 PM
Re: beambe post# 592
Post # of 1060 
CEMI's COVID-19 diagnostic tests results in 15 minutes

We deliver high-quality diagnostic tests that provide results in approximately 15 minutes using fingertip blood, nasal swabs and other sample types


Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu
Apr 1, 2021

In-licensed Rapid Point-of-Care Test Available for Use in Detecting COVID-19 Antigens, Flu A and Flu B from a Single Patient Sample in 15 Minutes

HAUPPAUGE, N.Y., April 01, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the commercial launch of an FDA Emergency Use Authorization-approved, in-licensed rapid point-of-care COVID-19/Flu A&B test, for use in decentralized and traditional testing settings. Product inventory is on-hand and immediately available for shipment to customers across the United States.

The rapid immunoassay test is approved for use in laboratories with a CLIA waiver license, produces results in 15 minutes and requires no instrumentation. The test simultaneously differentiates SARS-CoV-2 antigens and influenza Type A and Type B infections from a single swab.

“As COVID-19 converges with the flu, it is critical for physicians to be able to quickly differentiate between these viruses at the point-of-care, which present with nearly identical symptoms, in order to take appropriate clinical actions and maximize efficient use of healthcare resources,” said Charles Caso, Vice President of Sales and Marketing for Chembio. “Based on recent research, we expect that the spread of COVID-19 will eventually transition from a pandemic to an endemic state, with the virus surviving among the population at a lower incidence. In this scenario, coupled with the return to normalcy in society, we see COVID-19 testing remaining a crucial and integral component of broader respiratory testing.”

About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.

DPP is Chembio’s registered trademark, and the Chembio logo is Chembio’s trademark. For convenience, these trademarks appear in this release without ® or ™ symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademark.

Brian Johnston
Gilmartin Group


follow me on BLUE SKY BREAKOUT
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences